

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**Characterisation of the synergistic vancomycin-furazolidone
action against *Escherichia coli*.**

**A thesis presented in partial fulfilment of the requirements for the
degree of**

**Masters
in
Biochemistry**

**at Massey University, Manawatū,
New Zealand.**

Raveen Marlon Weerasinghe

2017

Abstract

The use of antibiotic combinations is garnering increased interest in the recent years due to the spread of antibiotic-resistant bacteria. The shortage of antibacterial therapy options is particularly severe for infections caused by Gram-negative bacteria, due to the formidable barrier to molecules > 600 Da imposed by the outer membrane. Vancomycin is a large glycopeptide antibiotic to which the outer membrane is poorly permeable, hence the minimal inhibitory concentration of this antibiotic for *Escherichia coli* is very high (~ 500 mg/L). Due to the resistance of *E. coli* and other Gram-negative pathogens to an increasing number of < 600 Da antibiotics including beta lactams, aminoglycosides and quinolones, enabling vancomycin use on Gram-negative bacteria would be valuable. Furazolidone was reported to increase sensitivity of *E. coli* to vancomycin, and this interaction has been investigated in this thesis in order to explore the potential of the vancomycin-furazolidone combination for clinical applications. The initial analysis of the vancomycin-furazolidone synergy demonstrated that their interaction is synergistic rather than merely additive. Furthermore, effectiveness of this combination for growth inhibition and eradication of *E. coli* biofilm was investigated. However, despite the synergy between vancomycin and furazolidone, the concentration of vancomycin in combinations required for growth inhibition and killing of *E. coli* in a planktonic mode and as a biofilm was above the nephrotoxicity (toxicity in the kidneys) threshold and therefore too high to treat infections with this organism systemically. However, by adding deoxycholic acid to the combination, the bactericidal vancomycin concentration was decreased below the nephrotoxicity threshold. The mechanism of synergy in the planktonic mode of growth was investigated through the analysis of *E. coli* gene-knock-out mutants and it was observed that TolC, the outer membrane channel common to a number of efflux systems (exporting enterobactin, xenobiotics and metabolites) is likely to be involved in vancomycin-furazolidone synergy. However, it was not possible to reliably pinpoint any particular efflux pump or enterobactin accumulation as factors in synergy. Using the genetic approach, it was found that DNA excision repair endonuclease UvrABC was ruled out as a factor involved in synergy. Overall this study characterised the synergy between vancomycin and furazolidone, initiated the enquiry into the mechanisms of interaction between these two antibiotics and examined its effectiveness against biofilms.

Acknowledgements

I would first like to thank my supervisor, Associate Professor Jasna Rakonjac for giving me the opportunity to do this MSc under her on such short notice and for all the guidance and patience that she has shown me over this past year. Her knowledge and expertise in this field has been of tremendous help during this study and has prevented many headaches.

I would also like to thank my fellow lab mates from Helipad/D4.01: Vuong, Sofia, Stefanie, Fabian, Georgia and Marina. Thank you, guys, for all the assistance and help you have given me and for making my time at Massey a great and a memorable experience. I'll miss you guys! I would like to extend my thanks to IFS in Massey University as a whole. It is a truly wonderful place to study and the skills that I have gained here will no doubt be extremely useful for later in life.

Also to my friends in Otago: Aran, Will, Shirley, Chris and Jithendra. Thank you, guys, for all your support during my years at Otago and in my decision to move to Massey and for being good mates throughout all these years.

Finally, I would like to thank my parents, Raja and Manel. I could not have done this year without either of you and words cannot express all the love and support you have shown me. I would also like to apologise to you for putting up with me during my whinging sessions which were enough to last a lifetime.

Abbreviations

%	Percentage
\$	Dollars
°C	Degrees Celsius
μL	Microlitre
μm	Micrometre
8-OHdG	8-hydroxydeoxyguanosine
ABC	Adenosine triphosphate binding cassette
AMR	Antimicrobial resistance
ATP	Adenosine triphosphate
CaCl ₂	Calcium chloride
CAUTI	Catheter associated infections
CDC	Centres for Disease Control and Prevention
CFU/mL	Colony forming units per millilitre
Da	Daltons
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DOC	Sodium deoxycholate
ECM	Extracellular matrix
ESBL	Extended-spectrum beta-lactamase
FICI	Fractional Inhibitory Concentration Index
g	Grams
g/L	Grams per litre
HepG2	Hepatoma

kDa	Kilodaltons
Km ^R	Kanamycin resistance marker
kPa	Kilopascals
LPS	Lipopolysaccharide
MATE	Multidrug and toxic efflux
MBC	Minimal Bactericidal Concentration
MBEC	Minimal Biofilm Eradication Concentration
MBIC	Minimal Biofilm Inhibitory Concentration
mg/kg	Milligram per kilogram
mg/kg/day	Milligram per kilogram per day
mg/L	Milligram per litre
MgSO ₄	Magnesium sulfate
MIC	Minimal Inhibitory Concentration
mL	Millilitre
mM	Millimolar
MRSA	Methicillin resistant <i>S. aureus</i>
Na	Sodium
nm	Nanometre
NO	Nitric oxide
NZ	New Zealand
OD	Optical density
ORF	Open reading frame
PMF	Proton motive force
RND	Resistance nodulation division

Rpm	Revolutions per minute
ROS	Reactive oxygen species
SOC	Super Optimal broth with Catabolite repression
SMR	Small multidrug resistance
USA	United States of America

Table of Contents

1	Introduction	1
1.1	Antimicrobial resistance	1
1.2	Antimicrobial resistance in Gram-negative bacteria.....	2
1.3	Efflux pumps.....	2
1.3.1	Structure of the AcrAB-TolC system	3
1.3.2	Function of the AcrAB-TolC system.....	7
1.4	Vancomycin	7
1.4.1	Mechanism of action.....	7
1.4.2	Implications	10
1.5	Furazolidone.....	11
1.5.1	Mechanism of action.....	11
1.5.2	Implications	12
1.6	Sodium Deoxycholate	13
1.7	Drug combinations.....	13
1.7.1	Evaluation of interactions	14
1.7.2	Targets and mechanisms	14
1.8	Biofilms.....	15
1.8.1	Structure.....	15
1.8.2	Clinical significance	18
1.9	Hypothesis and aims	19
2	Materials and methods.....	20
2.1	Media preparation	20
2.2	Bacterial strains.....	20
2.3	Antibiotics.....	22
2.4	Minimal inhibitory concentration (MIC)	23
2.4.1	Checkerboard assay	23
2.4.2	Minimal Bactericidal Concentration (MBC)	24
2.5	Time-kill assay.....	24
2.6	Competent cells.....	25
2.7	FLP recombination in <i>E. coli</i>	25
2.8	P1 transduction.....	26
2.9	Biofilms.....	27
2.9.1	Growing biofilms.....	27
2.9.2	Minimal biofilm inhibition concentration (MBIC).....	27

2.9.3	Minimal biofilm eradication (killing) concentration (MBEC)	27
3	Results	28
3.1	Quantifying synergy between vancomycin and furazolidone for <i>E. coli</i>	28
3.1.1	MICs for vancomycin and furazolidone against <i>E. coli</i>	28
3.1.2	Interaction between vancomycin and furazolidone in growth inhibition of <i>E. coli</i>	28
3.2	Bactericidal effect of vancomycin and furazolidone in combination	32
3.3	Investigation of the synergy mechanism: the role of efflux pumps	35
3.3.1	Efflux pump mutant screen	35
3.3.2	Checkerboard analysis of TolC efflux pump system mutants	37
3.4	Enterobactin synthesis and transport	40
3.5	DNA repair	45
3.6	Biofilms	47
3.6.1	Minimal Biofilm Inhibitory Concentration (MBIC)	47
3.6.2	Minimal Biofilm Eliminating (cell killing) Concentration (MBEC)	47
3.7	Addition of DOC to the vancomycin-furazolidone combination	52
4	Discussion	53
4.1	Synergy between vancomycin and furazolidone	53
4.2	Investigation of the mechanisms of synergy	55
4.2.1	Efflux pump system	55
4.2.2	Enterobactin synthesis and transport	58
4.2.3	DNA as a target	60
4.3	Biofilms	62
4.4	Effects of DOC on the vancomycin-furazolidone synergy	64
5	Conclusions	66
6	Future directions	67
6.1	Synergy	67
6.2	Furazolidone mechanism of action	67
6.3	Inhibition of biofilms	68
7	References	69
8	Appendix 1. tolC operon	83
9	Appendix 2. acrA operon	84
10	Appendix 3. entC operon	85

List of Figures

Figure 1: Diagram of the AcrAB-TolC efflux system.....	5
Figure 2: Structure of the AcrB trimer	6
Figure 3: Mechanism of vancomycin during peptidoglycan biosynthesis.	8
Figure 4: Vancomycin binding sites.	9
Figure 5: Steps involved in biofilm formation.	17
Figure 6: Isobologram comparing the synergy of the vancomycin furazolidone combination against the laboratory strains, BW25113 and KI508.	31
Figure 7: Time-kill assay for the vancomycin and furazolidone combination against <i>E. coli</i> BW25113.	34
Figure 8: Effects of the kanamycin resistance marker in the $\Delta tolC$ and $\Delta acrA$ alleles on vancomycin and furazolidone interaction.	38
Figure 9: Effect of the $\Delta tolC$ and $\Delta acrA$ mutations on the interaction between vancomycin and furazolidone.	39
Figure 10: Effects of the kanamycin resistance marker on the synergy changes in the $\Delta entC$ single $\Delta tolC$ $\Delta entC$ double mutant strains.	43
Figure 11: Effects of $\Delta tolC$ $\Delta entC$ single and double $\Delta tolC$ $\Delta entC$ mutants on the interaction between vancomycin and furazolidone.	44
Figure 12: Effect of the excision repair system mutant $\Delta uvrA$ on the vancomycin and furazolidone interaction.	46
Figure 13: Susceptibility of <i>E. coli</i> BW25113 biofilms against vancomycin and furazolidone.	50
Figure 14: Checkerboard analysis of the BW25113 (wild type) biofilm killing (eradication) by vancomycin and furazolidone combinations.	51

List of tables

Table 1: List of <i>E. coli</i> strains used.....	21
Table 2: List of antibiotics and concentrations used.....	22
Table 3: FICI scores for the vancomycin and furazolidone antibiotic combinations against <i>E. coli</i> laboratory strain BW25113 obtained from the checkerboard assay.	30
Table 4: FICI scores for vancomycin and furazolidone antibiotic combinations against <i>E. coli</i> laboratory strain KI508 obtained from the checkerboard assay.	30
Table 5: Titres of viable cells in the inhibitory vancomycin and furazolidone concentration combinations.	33
Table 6: MICs for vancomycin and furazolidone against <i>E. coli</i> mutants involved in the TolC efflux systems.	36
Table 7: MICs for vancomycin and furazolidone against the <i>E. coli</i> mutants involved in the enterobactin synthesis and transport system.	42